Page last updated: 2024-11-02

pioglitazone and Chronic Hepatitis C

pioglitazone has been researched along with Chronic Hepatitis C in 11 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)."9.19A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014)
"Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone."9.16Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012)
" The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naïve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study."9.14Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. ( Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y, 2010)
"We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study)."9.13Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. ( Genné, D; Golay, A; Negro, F; Overbeck, K, 2008)
"To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients."7.85Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017)
"Pioglitazone was well tolerated and no one discontinued due to side effects."6.80Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015)
": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment."6.79Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. ( Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P, 2014)
"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0."6.77Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012)
"Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)."5.19A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014)
"Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone."5.16Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012)
" The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naïve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study."5.14Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. ( Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y, 2010)
"We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study)."5.13Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. ( Genné, D; Golay, A; Negro, F; Overbeck, K, 2008)
"To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients."3.85Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017)
"Pioglitazone was well tolerated and no one discontinued due to side effects."2.80Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. ( Benator, D; Chairez, C; Hadigan, C; Kleiner, DE; Kovacs, JA; Matthews, L; McManus, M; Morse, CG; Nettles, MJ; Zemanick, K, 2015)
": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment."2.79Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. ( Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P, 2014)
"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0."2.77Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's8 (72.73)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Khan, IM1
Malik, BR1
Randhawa, FA1
Butt, NF1
Malik, U1
Hamid, S1
Ullman, K1
Marks, KM1
Kitch, D1
Chung, RT1
Hadigan, C2
Andersen, J1
Tien, P1
Luetkemeyer, A1
Alston-Smith, B1
Glesby, MJ1
Hsu, CS1
Hsu, SJ1
Lin, HH1
Tseng, TC1
Wang, CC1
Chen, DS1
Kao, JH1
Matthews, L1
Kleiner, DE1
Chairez, C1
McManus, M1
Nettles, MJ1
Zemanick, K1
Morse, CG1
Benator, D1
Kovacs, JA1
Overbeck, K1
Genné, D1
Golay, A1
Negro, F1
Serfaty, L1
Fartoux, L1
Poupon, R1
Khattab, M1
Emad, M1
Abdelaleem, A1
Eslam, M1
Atef, R1
Shaker, Y1
Hamdy, L1
Harrison, SA1
Hamzeh, FM1
Han, J1
Pandya, PK1
Sheikh, MY1
Vierling, JM1
Chojkier, M1
Elkhayat, H1
Sabry, D1
Donohue, M1
Buck, M1
Füessl, HS1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451]Phase 1/Phase 2120 participants (Actual)Interventional2020-07-27Completed
Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection[NCT00742326]Phase 413 participants (Actual)Interventional2008-08-31Terminated (stopped due to Enrollment stopped prior to complete enrollment due to slow accrual)
A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975]Phase 20 participants (Actual)Interventional2008-10-31Withdrawn (stopped due to Study was completed in another site)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.

Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline (NCT00742326)
Timeframe: 48 weeks

Interventionpercentage of hepatic fat on MRS (Mean)
Pioglitazone-7.43
Placebo-2.17

Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo

Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values (NCT00742326)
Timeframe: 48 weeks

Interventionmg*120 minutes/dL (Mean)
Pioglitazone-31
Placebo11

Trials

7 trials available for pioglitazone and Chronic Hepatitis C

ArticleYear
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
    Journal of acquired immune deficiency syndromes (1999), 2014, Mar-01, Volume: 65, Issue:3

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Hepaci

2014
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2014, Volume: 113, Issue:10

    Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination

2014
Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:10

    Topics: Adult; Coinfection; Double-Blind Method; Fatty Liver; Female; Hepatitis C, Chronic; Histocytochemist

2015
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
    Journal of hepatology, 2008, Volume: 49, Issue:2

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; H

2008
Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chro

2010
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2

    Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Stu

2012
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G

2012

Other Studies

4 other studies available for pioglitazone and Chronic Hepatitis C

ArticleYear
Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
    JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:12

    Topics: Adult; Antiviral Agents; Blood Glucose; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; I

2017
THE HEPATITIS/DIABETES CONNECTION The Effect of Hep C cures on Type 2 diabetes still unknown.
    Diabetes self-management, 2016, Volume: 33, Issue:5

    Topics: Antiviral Agents; Comorbidity; Diabetes Mellitus, Type 2; Hepatitis B; Hepatitis B Vaccines; Hepatit

2016
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
    Journal of hepatology, 2009, Volume: 50, Issue:6

    Topics: Adult; Antiviral Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Hepatitis C, Chronic;

2009
[Fatty liver. Not only ultrasound to be relied on!].
    MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39

    Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis; Hepatitis C; Hep

2003